JP7471224B2 - Ｈ因子増強抗体及びその使用 - Google Patents

Ｈ因子増強抗体及びその使用 Download PDF

Info

Publication number
JP7471224B2
JP7471224B2 JP2020538984A JP2020538984A JP7471224B2 JP 7471224 B2 JP7471224 B2 JP 7471224B2 JP 2020538984 A JP2020538984 A JP 2020538984A JP 2020538984 A JP2020538984 A JP 2020538984A JP 7471224 B2 JP7471224 B2 JP 7471224B2
Authority
JP
Japan
Prior art keywords
antibody
fragment
sequence
seq
less
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020538984A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021510523A (ja
JP2021510523A5 (https=
Inventor
タコ・ヴィレム・カウペルス
ディアナ・ヴァウテルス
マリア・クラーラ・ブラウエル
リシャルト・ベンヤミン・パウ
Original Assignee
シュティッヒティング・サンコン・ブロードフォールジーニング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シュティッヒティング・サンコン・ブロードフォールジーニング filed Critical シュティッヒティング・サンコン・ブロードフォールジーニング
Publication of JP2021510523A publication Critical patent/JP2021510523A/ja
Publication of JP2021510523A5 publication Critical patent/JP2021510523A5/ja
Priority to JP2023067121A priority Critical patent/JP2023089191A/ja
Application granted granted Critical
Publication of JP7471224B2 publication Critical patent/JP7471224B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2020538984A 2018-01-15 2019-01-15 Ｈ因子増強抗体及びその使用 Active JP7471224B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023067121A JP2023089191A (ja) 2018-01-15 2023-04-17 Ｈ因子増強抗体及びその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18151726 2018-01-15
EP18151726.9 2018-01-15
PCT/NL2019/050018 WO2019139481A1 (en) 2018-01-15 2019-01-15 Factor h potentiating antibodies and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023067121A Division JP2023089191A (ja) 2018-01-15 2023-04-17 Ｈ因子増強抗体及びその使用

Publications (3)

Publication Number Publication Date
JP2021510523A JP2021510523A (ja) 2021-04-30
JP2021510523A5 JP2021510523A5 (https=) 2022-01-04
JP7471224B2 true JP7471224B2 (ja) 2024-04-19

Family

ID=60972152

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020538984A Active JP7471224B2 (ja) 2018-01-15 2019-01-15 Ｈ因子増強抗体及びその使用
JP2023067121A Pending JP2023089191A (ja) 2018-01-15 2023-04-17 Ｈ因子増強抗体及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023067121A Pending JP2023089191A (ja) 2018-01-15 2023-04-17 Ｈ因子増強抗体及びその使用

Country Status (11)

Country Link
US (2) US11377487B2 (https=)
EP (1) EP3740502A1 (https=)
JP (2) JP7471224B2 (https=)
KR (2) KR102896085B1 (https=)
CN (1) CN111868083B (https=)
AU (1) AU2019206207B2 (https=)
BR (1) BR112020014399A2 (https=)
CA (1) CA3088507A1 (https=)
IL (1) IL276008A (https=)
MX (1) MX2020007555A (https=)
WO (1) WO2019139481A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102896085B1 (ko) * 2018-01-15 2025-12-08 스티흐팅 산퀸 불드포르지닝 인자 h 강화 항체 및 이의 사용
TWI851771B (zh) * 2019-07-17 2024-08-11 美商雙子治療子公司 因子ｈ增強抗體及其用途
CN114560941B (zh) * 2020-11-27 2024-01-16 广东东阳光药业股份有限公司 Cldn18.2的抗体及其应用
US20250121090A1 (en) * 2021-07-30 2025-04-17 R.P. Scherer Technologies, Llc Antibody-Drug Conjugates and Methods of Use Thereof
CN116355860A (zh) * 2021-12-28 2023-06-30 四川远大蜀阳药业有限责任公司 分泌抗h因子抗体的杂交瘤细胞株、抗h因子抗体及其应用
CN116041521B (zh) * 2022-03-21 2023-11-03 南京蓬勃生物科技有限公司 靶向Siglec-15的单克隆抗体及其应用
NL2032398B1 (en) * 2022-07-06 2024-01-23 Academisch Ziekenhuis Leiden Bispecific antibody and uses thereof
CN118878671B (zh) * 2024-07-04 2025-09-30 南京农业大学 抗兽疫链球菌SzM蛋白的猪源化单克隆抗体

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013508287A (ja) 2009-10-14 2013-03-07 ヤンセン バイオテツク，インコーポレーテツド 抗体を親和性成熟する方法
JP2013510164A (ja) 2009-11-04 2013-03-21 ファブラス エルエルシー 親和性成熟に基づく抗体最適化方法
JP2017525362A (ja) 2014-08-20 2017-09-07 シュティヒティング サンクイン ブロエドフォールツィーニング Ｈ因子を強化する抗体及びその用途
JP2017532952A (ja) 2014-08-27 2017-11-09 メモリアル スローン−ケタリング キャンサー センター 抗体、組成物および使用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102896085B1 (ko) * 2018-01-15 2025-12-08 스티흐팅 산퀸 불드포르지닝 인자 h 강화 항체 및 이의 사용
TWI851771B (zh) * 2019-07-17 2024-08-11 美商雙子治療子公司 因子ｈ增強抗體及其用途

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013508287A (ja) 2009-10-14 2013-03-07 ヤンセン バイオテツク，インコーポレーテツド 抗体を親和性成熟する方法
JP2013510164A (ja) 2009-11-04 2013-03-21 ファブラス エルエルシー 親和性成熟に基づく抗体最適化方法
JP2017525362A (ja) 2014-08-20 2017-09-07 シュティヒティング サンクイン ブロエドフォールツィーニング Ｈ因子を強化する抗体及びその用途
JP2017532952A (ja) 2014-08-27 2017-11-09 メモリアル スローン−ケタリング キャンサー センター 抗体、組成物および使用

Also Published As

Publication number Publication date
US11377487B2 (en) 2022-07-05
JP2023089191A (ja) 2023-06-27
WO2019139481A1 (en) 2019-07-18
KR20200110688A (ko) 2020-09-24
US20220356235A1 (en) 2022-11-10
KR102896085B1 (ko) 2025-12-08
AU2019206207A1 (en) 2020-08-13
JP2021510523A (ja) 2021-04-30
EP3740502A1 (en) 2020-11-25
IL276008A (en) 2020-08-31
CN111868083B (zh) 2025-02-11
CA3088507A1 (en) 2019-07-18
MX2020007555A (es) 2021-01-15
US20210054059A1 (en) 2021-02-25
KR20250171487A (ko) 2025-12-08
CN111868083A (zh) 2020-10-30
BR112020014399A2 (pt) 2020-12-29
AU2019206207B2 (en) 2025-04-10

Similar Documents

Publication Publication Date Title
JP7471224B2 (ja) Ｈ因子増強抗体及びその使用
US20240336676A1 (en) Factor h potentiating antibodies and uses thereof
JP2021178857A (ja) Ｈ因子を強化する抗体及びその用途
AU2020313981B2 (en) Factor H potentiating antibodies and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211119

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211119

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20221012

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221017

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230417

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230731

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231130

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240118

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240311

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240409

R150 Certificate of patent or registration of utility model

Ref document number: 7471224

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150